Heron Therapeutics
HRTX
171 hedge funds and large institutions have $272M invested in Heron Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 66 increasing their positions, 31 reducing their positions, and 17 closing their positions.
3,671% more call options, than puts
Call options by funds: $3.28M | Put options by funds: $87K
113% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 31
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
4.25% more ownership
Funds ownership: 81.92% → 86.17% (+4.3%)
4% more funds holding
Funds holding: 165 → 171 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less capital invested
Capital invested by funds: $275M → $272M (-$2.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.18M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.51M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.35M |
| 4 |
BlackRock
New York
|
+$3.14M |
| 5 |
Morgan Stanley
New York
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.5M |
| 2 |
Millennium Management
New York
|
-$1.84M |
| 3 |
OCM
Orchard Capital Management
Chicago,
Illinois
|
-$1.58M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$768K |
| 5 |
CC
Clearline Capital
New York
|
-$414K |
HRTX Hedge Fund Activity: Q2 2025 in Review
171 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2025, worth a combined $272M — down 0.87% from $275M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new HRTX positions and 17 closed out — a net gain of 7 holders — while 66 added to existing stakes and 31 trimmed.
The largest buyer was UBS Group, adding an estimated $6.18M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $10.5M sold.
- 171 institutional investors held Heron Therapeutics (HRTX) as of Q2 2025, up from 165 in Q1 2025.
- Funds reported $272M of Heron Therapeutics stock for Q2 2025, down 0.87% quarter-over-quarter.
- 24 funds opened new Heron Therapeutics positions in Q2 2025 and 17 closed out, a net change of +7 holders.
- The largest Heron Therapeutics buyer in Q2 2025 was UBS Group, an estimated $6.18M added.
- The largest Heron Therapeutics seller in Q2 2025 was Point72 Asset Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2025.